Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505076

2023-01-01

Abstract:Figure S7 shows the model of anti-MET VHH pool overcoming MET-targeted cancer therapeutic resistance.

What problem does this paper attempt to address?

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505091

2023-01-01

Abstract:Figure S2 shows the specificity of anti-MET VHH pool on MET in killing cancer cells.
Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505085

2023-01-01

Abstract:Figure S4 shows the long-term role of anti-MET VHH pool in treating mice.
Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505088.v1

2023-01-01

Abstract:Figure S3 shows the efficacy of anti-MET VHH pool on tumor growth in individual mouse.
Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Hang-Ping Yao,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.drudis.2020.11.002

IF: 8.369

2021-01-01

Drug Discovery Today

Abstract:•Cancerous MET overexpression is a common pathological feature manifested by genetic, molecular, and cellular abnormalities.•Conventional therapeutic antibodies targeting MET, under clinical trials for almost 10 years, have made little progress with various setbacks.•Novel biotherapeutics, such as bispecific antibodies, antibody-drug conjugates, and their combination, are under anti-MET clinical trials.•Amivantamab, a MET/EGFR bispecific antibody, has been granted the Breakthrough Therapy Designation status for treatment of advanced NSCLC.•An emerging era of antibody-based biotherapeutics for treatment of cancer overexpressing MET is in the horizon.
Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Jianqun Kou,Ben Staal,Phillip R. Musich,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Tam Angela,Alan Huang,Huaixiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1158/1538-7445.am2018-lb-015

IF: 11.2

2018-01-01

Cancer Research

Abstract:Abstract Purpose: MET inhibitors are in clinical trials against several cancer types, but the mechanisms toward vulnerability remain elusive. Here we characterized the molecular basis of MET amplification (METamp) and HGF-autocrine driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies. Experimental Design: METamp (MKN45 and MHCC97H) and HGF-autocrine activation (JHH5 and U87) cells were treated by the MET kinase inhibitor (INC280) and the anti-MET monoclonal antibody (MetMab) to determine the sensitivity and biological responses in vitro. Tumor inhibition was evaluated in vivo using SCID and SCIDhgf mouse models, respectively. HGF-mediated angiogenesis was measured by using the human endothelial cells (HUVEC) tube formation assay. Results: MKN45 and MHCC97H cells are more sensitive than JHH5 and U87 cells to INC280 treatment but are unresponsive to MetMab. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although INC280 and MetMab showed a moderate inhibitory effect on - JHH5 and U87 cells in vitro, both treatments potently suppressed tumor growth in mouse models. We found that HGF stimulation promotes human HUVEC cell tube formation via the Src pathway. INC280 or MetMab inhibited tube formation; thus in HGF-autocrine tumors, the endothelial cells are the secondary targets of tumor-derived HGF and MET inhibition. Conclusion: METamp and HGF-autocrine activation favor different molecular mechanisms, such as a DNA damage response or angiogenesis. Because individual types of MET oncogenic activation may respond to MET inhibitors differently, combination strategies should be developed based upon the molecular subtypes of the tumors. Citation Format: Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie. Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-015.
Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

John O. DaSilva,Katie Yang,Andrés E. Perez Bay,Julian Andreev,Peter Ngoi,Erica Pyles,Matthew C. Franklin,Drew Dudgeon,Ashique Rafique,Anthony J. Dore,Frank J. Delfino,Terra Potocky,Robert G. Babb,Gang Chen,Douglas MacDonald,William C. Olson,Gavin Thurston,Christopher Daly

DOI: https://doi.org/10.1158/1078-0432.22479116

2023-01-01

Abstract:Supplementary figure legends and methods
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Xing Huang,Enliang Li,Hang Shen,Xun Wang,Tianyu Tang,Xiaozhen Zhang,Jian Xu,Zengwei Tang,Chengxiang Guo,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.3389/fcell.2020.00152

IF: 5.5

2020-01-01

Frontiers in Cell and Developmental Biology

Abstract:Among hundreds of thousands of signal receptors contributing to oncogenic activation, tumorigenesis, and metastasis, the hepatocyte growth factor (HGF) receptor - also called tyrosine kinase MET - is a promising target in cancer therapy as its axis is involved in several different cancer types. It is also associated with poor outcomes and is involved in the development of therapeutic resistance. Several HGF/MET-neutralizing antibodies and MET kinase-specific small molecule inhibitors have been developed, resulting in some context-dependent progress in multiple cancer treatments. Nevertheless, the concomitant therapeutic resistance largely inhibits the translation of such targeted drug candidates into clinical application. Until now, numerous studies have been performed to understand the molecular, cellular, and upstream mechanisms that regulate HGF/MET-targeted drug resistance, further explore novel strategies to reduce the occurrence of resistance, and improve therapeutic efficacy after resistance. Intriguingly, emerging evidence has revealed that, in addition to its conventional function as an oncogene, the HGF/MET axis stands at the crossroads of tumor autophagy, immunity, and microenvironment. Based on current progress, this review summarizes the current challenges and simultaneously proposes future opportunities for HGF/MET targeting for therapeutic cancer interventions.
Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Hang-Ping Yao,Rachel Hudson,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.bbcan.2020.188425

2020-01-01

Abstract:Advanced epithelial cancers such as gastric, lung, and pancreatic tumors are featured by invasive proliferation, distant metastasis, acquired chemoresistance, and tumorigenic stemness. For the last decade, molecular-targeted therapies using therapeutic antibodies, small molecule kinase inhibitors and immune-checkpoint blockades have been applied for these diseases with significant clinical benefits. Nevertheless, there is still a large gap to achieve curative outcomes. MET (mesenchymal-epithelial transition protein), a receptor tyrosine kinase, is a tumorigenic determinant that regulates epithelial cancer initiation, progression, and malignancy. Increased MET expression also has prognostic value for cancer progression and patient survival. These features provide the rationale to target MET for cancer treatment. In this review, we discuss the importance of MET in epithelial tumorigenesis and the development of antibody-based biotherapeutics, including bispecific antibodies and antibody-drug conjugates, for clinical application. The findings from both preclinical and clinical studies highlight the potential of MET-targeted biotherapeutics for cancer therapy in the future.
Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Hang-Ping Yao,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1177/17588359211006957

2021-01-01

Therapeutic Advances in Medical Oncology

Abstract:Aberrant expression and/or activation of the MET receptor tyrosine kinase is characterized by genomic recombination, gene amplification, activating mutation, alternative exon-splicing, increased transcription, and their different combinations. These dysregulations serve as oncogenic determinants contributing to cancerous initiation, progression, malignancy, and stemness. Moreover, integration of the MET pathway into the cellular signaling network as an addiction mechanism for survival has made this receptor an attractive pharmaceutical target for oncological intervention. For the last 20 years, MET-targeting small-molecule kinase inhibitors (SMKIs), conventional therapeutic monoclonal antibodies (TMABs), and antibody-based biotherapeutics such as bispecific antibodies, antibody-drug conjugates (ADC), and dual-targeting ADCs have been under intensive investigation. Outcomes from preclinical studies and clinical trials are mixed with certain successes but also various setbacks. Due to the complex nature of MET dysregulation with multiple facets and underlying mechanisms, mechanism-based validation of MET-targeting therapeutics is crucial for the selection and validation of lead candidates for clinical trials. In this review, we discuss the importance of various types of mechanism-based pharmaceutical models in evaluation of different types of MET-targeting therapeutics. The advantages and disadvantages of these mechanism-based strategies for SMKIs, conventional TMABs, and antibody-based biotherapeutics are analyzed. The demand for establishing new strategies suitable for validating novel biotherapeutics is also discussed. The information summarized should provide a pharmaceutical guideline for selection and validation of MET-targeting therapeutics for clinical application in the future.
Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433516

2023-01-01

Abstract:This file shows the antibodies used in the study.
Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Xiangheng Chen,Zhonghai Guan,Jun Lu,Haohao Wang,Zhongkun Zuo,Fei Ye,Jiangsheng Huang,Lisong Teng

DOI: https://doi.org/10.7150/jca.20964

IF: 3.9

2018-01-01

Journal of Cancer

Abstract:cMet signaling pathway is involved in the resistance to anti-VEGF therapy and cMet overexpression is associated with tumor progression and poor prognosis. In this study, the expression of cMet in 146 Chinese colorectal cancer (CRC) patients was examined by immunohistochemistry staining. Our data demonstrated that cMet overexpression rate was 42.5% (62/146) and cMet overexpression was closely correlated with distant metastasis of CRC. Using CRC patient-derived xenograft (PDX) mouse models we investigated antitumor activity of a novel selective cMet inhibitor volitinib alone or in combination with anti-VEGF inhibitor apatinib in vivo. Our results showed that combination treatment significantly inhibited tumor growth in two PDX models. While volitinib treatment alone induced moderate improvement in tumor growth inhibition, combination treatment synergistically reduced microvessel density, suppressed proliferation, and increased apoptosis in PDX models. Further analysis showed synergistic inhibition of MAPK and PI3K/Akt pathways by volitinib and apatinib. Taken together, our data provide a rationale to targeting both cMet and VEGF in the treatment of cMet overexpressing CRC in clinical trials.
Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Jianqun Kou,Phillip R. Musich,Ben Staal,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Weizhong Wu,Angela Tam,Alan Huang,Huai-Xiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1186/s12967-018-1628-y

IF: 8.44

2018-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive.METHODS:With the goal to investigate the molecular basis of MET amplification (METamp) and hepatocyte growth factor (HGF) autocrine-driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies, we compared cancer cells harboring METamp (MKN45 and MHCCH97H) or HGF-autocrine (JHH5 and U87) for their sensitivity and downstream biological responses to a MET-TKI (INC280) and an anti-MET monoclonal antibody (MetMab) in vitro, and for tumor inhibition in vivo.RESULTS:We find that cancer cells driven by METamp are more sensitive to INC280 than are those driven by HGF-autocrine activation. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although MetMab failed to inhibit METamp cell proliferation and tumor growth, both INC280 and MetMab reduced HGF-autocrine tumor growth. In addition, we also show that HGF stimulation promoted human HUVEC cell tube formation via the Src pathway, which was inhibited by either INC280 or MetMab. These observations suggest that in HGF-autocrine tumors, the endothelial cells are the secondary targets MET inhibitors.CONCLUSIONS:Our results demonstrate that METamp and HGF-autocrine activation favor different molecular mechanisms. While combining MET TKIs and ATM inhibitors may enhance the efficacy for treating tumors harboring METamp, a combined inhibition of MET and angiogenesis pathways may improve the therapeutic efficacy against HGF-autocrine tumors.
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

David L. Shattuck,Jamie K. Miller,Kermit L. Carraway,Colleen Sweeney

DOI: https://doi.org/10.1158/0008-5472.can-07-5962

IF: 11.2

2008-03-01

Cancer Research

Abstract:Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met.

oncology
Figure S3 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22546687

2023-01-01

Abstract:One MET-FISH-positive tumor was identified as negative by NGS
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Seung Yeon Oh,You Won Lee,Eun Ji Lee,Jae Hwan Kim,YoungJoon Park,Seong Gu Heo,Mi Ra Yu,Min Hee Hong,John DaSilva,Christopher Daly,Byoung Chul Cho,Sun Min Lim,Mi Ran Yun

DOI: https://doi.org/10.1158/1078-0432.CCR-22-2180

2023-01-04

Abstract:Purpose: MET amplification is a frequent mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and combined treatment with EGFR TKIs and MET TKIs has been explored as a strategy to overcome resistance. However, durable response is invariably limited by the emergence of acquired resistance. Here, we investigated the preclinical activity of REGN5093-M114, a novel antibody-drug conjugate targeting MET in MET-driven patient-derived models. Experimental design: Patient-derived organoids, patient-derived cells, or ATCC cell lines were used to investigate the in vitro/in vivo activity of REGN5093-M114. Results: REGN5093-M114 exhibited significant antitumor efficacy compared with MET TKI or unconjugated METxMET biparatopic antibody (REGN5093). Regardless of MET gene copy number, MET-overexpressed TKI-naïve EGFR-mutant NSCLC cells responded to REGN5093-M114 treatment. Cell surface MET expression had the most predictive power in determining the efficacy of REGN5093-M114. REGN5093-M114 potently reduced tumor growth of EGFR-mutant NSCLC with PTEN loss or MET Y1230C mutation after progression on prior osimertinib and savolitinib treatment. Conclusions: Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.
Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22546681.v1

2023-01-01

Abstract:One MET-FISH-negative patient was classified as having MET polysomy by NGS
Abstract 536: Breaking through ADCs resistance: Constructing preclinical enhertu-induced resistant model

Yuan Fang,Huiyi Wang,Jun Xing,Lu Yang,Jing Zhao,Xiang Gao,Cunxiang Ju

DOI: https://doi.org/10.1158/1538-7445.am2024-536

IF: 11.2

2024-03-23

Cancer Research

Abstract:Antibody-drug conjugates (ADCs) are compounds that combine the specificity of monoclonal antibodies (mAbs) with the cytotoxic payload of toxic substances. In recent years, ADCs have rapidly developed in the field of cancer therapy, particularly in the treatment of HER2-positive breast cancer. One representative example is Trastuzumab deruxtecan (Enhertu), which has become a new benchmark for anti-HER2 ADCs due to its excellent performance in clinical trials. Despite the impressive clinical outcomes of ADCs, some tumors in patients may still develop resistance to these drugs. Therefore, it is crucial to understand the mechanisms of resistance and develop strategies to overcome ADCs resistance. To achieve these goals, it is essential to establish and utilize preclinical models to study these resistance mechanisms. Preclinical models of resistance to ADCs have mainly been generated using human cultured cell lines. JIMT-1 is a HER2-positive breast cancer cell line that exhibits primary resistance to the anti-HER2 antibody trastuzumab and also shows resistance to trastuzumab-derived ADC T-DM1. However, we found that Enhertu significantly inhibited tumor growth in JIMT-1 xenograft models. We subjected JIMT-1 tumor tissues to continuous passage in mice and administered long-term drug induction. The tumor growth rate gradually increased, and the drug sensitivity decreased, resulting in the acquisition of an Enhertu-resistant tumor model. The obtained resistant tumor tissues not only include tumor cells themselves but also comprise fibroblasts, extracellular matrix, and other cellular components, enabling a more comprehensive investigation into the interactions between different cells within the tumor microenvironment (TME). We believe that the establishment of preclinical Enhertu-resistant models helps predict resistance that has not yet emerged clinically and provides references for future drug development. Citation Format: Yuan Fang, Huiyi Wang, Jun Xing, Lu Yang, Jing Zhao, Xiang Gao, Cunxiang Ju. Breaking through ADCs resistance: Constructing preclinical enhertu-induced resistant model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 536.

oncology
Quantitative Proteomics Discloses MET Expression in Mitochondria As a Direct Target of MET Kinase Inhibitor in Cancer Cells*

Tiannan Guo,Yi Zhu,Chee Sian Gan,Sze Sing Lee,Jiang Zhu,Haixia Wang,Xin Li,James Christensen,Shiang Huang,Oi Lian Kon,Siu Kwan Sze

DOI: https://doi.org/10.1074/mcp.m110.001776

IF: 7.381

2010-01-01

Molecular & Cellular Proteomics

Abstract:Cancer cells with MET overexpression are paradoxically more sensitive to MET inhibition than cells with baseline MET expression. The underlying molecular mechanisms are incompletely understood. Here, we have traced early responses of SNU5, a MET-overexpressing gastric cancer cell line, exposed to sublethal concentration of PHA-665752, a selective MET inhibitor, using iTRAQ-based quantitative proteomics. More than 1900 proteins were quantified, of which >800 proteins were quantified with at least five peptides. Proteins whose expression was perturbed by PHA-665752 included oxidoreductases, transfer/carrier proteins, and signaling proteins. Strikingly, 38% of proteins whose expression was confidently assessed to be perturbed by MET inhibition were mitochondrial proteins. Upon MET inhibition by a sublethal concentration of PHA-665752, mitochondrial membrane potential increased and mitochondrial permeability transition pore was inhibited concomitant with widespread changes in mitochondrial protein expression. We also showed the presence of highly activated MET in mitochondria, and striking suppression of MET activation by 50 nm PHA-665752. Taken together, our data indicate that mitochondria are a direct target of MET kinase inhibition, in addition to plasma membrane MET. Effects on activated MET in the mitochondria of cancer cells that are sensitive to MET inhibition might constitute a novel and critical noncanonical mechanism for the efficacy of MET-targeted therapeutics.
Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433522

2023-01-01

Abstract:This file describes supplementary figures.
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and is an Effective Indicator for Met-Targeting Therapy.

Qian Xie,Yanli Su,Karl Dykema,Jennifer Johnson,Julie Koeman,Valeria De Giorgi,Alan Huang,Robert Schlegel,Curt Essenburg,Liang Kang,Keiichi Iwaya,Shuhji Seki,Sok Kean Khoo,Boheng Zhang,Franco Buonaguro,Francesco M Marincola,Kyle Furge,George F Vande Woude,Nariyoshi Shinomiya

DOI: https://doi.org/10.1177/1947601913501075

2013-01-01

Genes & Cancer

Abstract:Hepatitis B virus (HBV) is a well-known cause of hepatocellular carcinoma (HCC), but the regulators effectively driving virus production and HCC progression remain unclear. By using genetically engineered mouse models, we show that overexpression of hepatocyte growth factor (HGF) accelerated HCC progression, supporting the genomic analysis that an up-regulated HGF signature is associated with poor prognosis in HBV-positive HCC patients. We show that for both liver regeneration and spontaneous HCC development there is an inclusive requirement for MET expression, and when HGF induces autocrine activation the tumor displays sensitivity to a small-molecule Met inhibitor. Our results demonstrate that HGF is a driver of HBV-induced HCC progression and may serve as an effective biomarker for Met-targeted therapy. MET inhibitors are entering clinical trials against cancer, and our data provide a molecular basis for targeting the Met pathway in hepatitis B-induced HCC.

Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Supplementary Table S1 from METTL1-Mediated M&lt;sup&gt;7&lt;/sup&gt;g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Figure S3 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Abstract 536: Breaking through ADCs resistance: Constructing preclinical enhertu-induced resistant model

Quantitative Proteomics Discloses MET Expression in Mitochondria As a Direct Target of MET Kinase Inhibitor in Cancer Cells*

Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and is an Effective Indicator for Met-Targeting Therapy.

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma